Dexcom
Dexcom, Inc., a leading player in the diabetes care industry, is headquartered in the United States. Founded in 1999, the company has pioneered continuous glucose monitoring (CGM) technology, significantly enhancing diabetes management for patients worldwide. With a strong presence in North America, Europe, and Asia, Dexcom focuses on developing innovative solutions that empower individuals to take control of their health. The company's flagship products, including the Dexcom G6 and G7 CGM systems, offer real-time glucose monitoring with exceptional accuracy and ease of use. These devices are distinguished by their ability to provide users with actionable insights, helping to prevent hypoglycaemic events and improve overall glycaemic control. Dexcom's commitment to innovation has solidified its position as a market leader, recognised for its contributions to diabetes management and patient care.
DitchCarbon Score
How does Dexcom's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Dexcom's score of 40 is higher than 65% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Dexcom's reported carbon emissions
In 2023, Dexcom, Inc. reported total carbon emissions of approximately 66,520,000 kg CO2e across all scopes. This includes about 6,652,000 kg CO2e from Scope 1 emissions, primarily from mobile and stationary combustion, and approximately 25,291,000 kg CO2e from Scope 2 emissions, which are market-based. The company also disclosed significant Scope 3 emissions, totalling around 325,942,000 kg CO2e, with the largest contributions from purchased goods and services (approximately 325,942,000 kg CO2e) and upstream transportation and distribution (about 45,009,000 kg CO2e). Comparatively, in 2022, Dexcom's emissions were lower, with about 4,768,000 kg CO2e from Scope 1 and approximately 13,614,000 kg CO2e from Scope 2. The company has shown a commitment to reducing its carbon footprint, although specific reduction targets have not been detailed in the latest reports. Notably, a near-term target commitment was removed in June 2023, indicating a shift in their climate strategy. Dexcom has not committed to a net-zero target as of the latest data, and their long-term climate commitments remain unspecified. The emissions data is sourced directly from Dexcom, Inc., with no cascading from a parent or related organization. The company operates within the healthcare equipment and supplies sector and is headquartered in the United States.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 2,044,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 9,371,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 1,257,000 | 0,000,000 | 0,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Dexcom is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
